Form 4: Halozyme Therapeutics SVP, Chief Legal Officer, Mark Howard Snyder, Reports Stock Option and Restricted Stock Unit Awards
SEC Form 4 Filing
Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- On February 20, 2025, Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, reported the acquisition of 22,603 stock options with an exercise price of $57.44.
- These options vest one-fourth on February 20, 2026, and then 1/48th monthly thereafter, expiring on February 20, 2035.
- Snyder also reported the acquisition of 21,327 restricted stock units, vesting one-fourth on each anniversary of the grant date, starting February 20, 2026.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option and RSU grants, indicating a neutral sentiment.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of stock-based compensation awarded to a company executive, which is a common practice in the biotechnology industry to incentivize and retain key personnel.
Stakeholder Impact
- The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders, incentivizing long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of transaction: Grant of stock options and restricted stock units. |
| 02/20/2026 | First vesting date for both stock options and restricted stock units. |
| 02/20/2035 | Expiration date for the stock options. |
| 02/21/2025 | Date of signature on the Form 4 filing. |
Keywords
Halozyme Therapeutics, Stock Options, Restricted Stock Units, Form 4, SVP, Chief Legal Officer, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.